BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2021.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the second quarter ended June 30, 2021 before the market opens on August 10, 2021.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases, announced that management will be participating in a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 2:20pm ET.

Theravance Biopharma, Inc. reported financial results for the second quarter of 2021.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021

Angion Biomedica Corp announced positive results from its Phase 1 study in healthy volunteers for ANG-3070, a novel oral tyrosine kinase receptor inhibitor being developed for the treatment of fibrotic diseases.

RELIEF THERAPEUTICS Holding AG reported that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for RLF-100, an inhaled formulation in development for the treatment of sarcoidosis.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application and granted Priority Review for Tecentriq® as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer whose tumors express PD-L1≥1%, as determined by an FDA-approved test.

According to the report, the global targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and is projected to expand at a moderate CAGR during the forecast period.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact. MR analysis, the Americas hematology diagnostics market is forecast to reach a valuation of US$ 451 Mn by 2031 end.